Transforming wAMD Treatment: Long-Lasting, Flexible Dosing with Suprachoroidal TKI Delivery
Time: 9:00 am
day: Day Two
Details:
- Address the high treatment burden of current anti-VEGF therapies for wAMD, highlighting the need for more sustainable and less frequent treatment but maintain the flexibility of anti-VEGF biologics
- Explore the benefits of TKIs in wAMD management, focusing on their pan-VEGF receptors blockage, extended drug delivery while acknowledging the limitations of current intravitreal anti-VEGF due to their modest longevity
- Looking at clinical prospects of wAMD formulations designed for suprachoroidal injection to deliver a precise daily dose to retinal and choroidal tissues, without full penetration of the eye wall, and low drug to off target tissue such as the lens, potentially revolutionizing the treatment regimen for wAMD patients with additional benefits such as no or very low risk of endophthalmitis and cataract
